Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs ResMed Inc. — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while ResMed Inc. trades at $198 (market cap $29.57B). The key difference: ResMed Inc. is far larger — about 17.5× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and ResMed Inc. pays the higher dividend (1.18%). Which is the better fit depends on your goals.
| AMC | RMD | |
|---|---|---|
Market Cap | $1.69B | $29.57B |
Sector | Media | Health |
52-Week High | $3.54 | $293.73 |
52-Week Low | $0.95 | $182.82 |
Enterprise Value | $9.28B | $28.76B |
Dividend Yield | 0.11% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
ResMed (RMD) trades at $203.87, down 2.2% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show a bullish trend with support at $202, while fundamentals reveal impressive 27.4% net margins and steady revenue growth from $5.15B in 2025 to projected $5.5B in 2026.
RMD presents a compelling investment case with 28% upside to analyst consensus target of $254.57, supported by strong cash flow generation and strategic business optimization. Key risks include competitive pressures in the sleep apnea market and potential market share challenges from new pharmaceutical treatments. The balanced analyst coverage (15 Buy, 15 Hold, 5 Sell) suggests cautious optimism amid the company's solid execution and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
